Ramazon Safarzoda Sharoffidin
Ramazon Safarzoda Sharoffidin has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Amin Tamadon
Department of Natural Sciences, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
16 shared publications - Nadiar Maratovich Mussin
Department of General Surgery No. 2, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
9 shared publications Nadiar M. Mussin
Department of General Surgery No. 2, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
6 shared publications- Afshin Zare
R&D Department, PerciaVista Co., Shiraz, Iran
4 shared publications Amin Tamadon
Department of Natural Sciences, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
3 shared publications- Kulyash R. Zhilisbayeva
Department of Languages, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
3 shared publications
Latest Publications
- 12 October 2026
- Published by SAGE Publications in Stem Cells and Development
- Vol. 35 (23-24) , 445-458
Translational Readiness of Dental Pulp Stem Cell and Extracellular-Vesicle Products: Manufacturing, Delivery, Safety, and Clinical Development
Dental pulp stem cells (DPSCs), stem cells from human exfoliated deciduous teeth (SHED), and extracellular vesicles (EVs) show regenerative potential, but clinical translation depends on a reproducible product–process–procedure system. This systematic scoping review mapped how DPSC- and EV-containing dental products are defined, manufactured, formulated, dosed, delivered, monitored, and regulated. Following Joanna Briggs Institute guidance (JBI) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR), an umbrella-assisted strategy combined two recent high-coverage reviews with a targeted update through July 15, 2026. Data were charted for source, characterization, carrier, dose, delivery, visualization, safety, outcomes, and manufacturing readiness; a nine-domain review-level framework (Translational Readiness Appraisal for Dental cell and EV products) summarized relative maturity without serving as a validated clinical score. The map comprised 52 unique primary reports and nine methodological or secondary sources. Scaffold-based DPSC/SHED studies generally favored cell-containing constructs, but most were heterogeneous short-term animal experiments. Small human studies of autologous DPSC or SHED products reported encouraging feasibility and few serious safety signals, yet were underpowered for effectiveness or uncommon harms. Dental EV evidence remained predominantly preclinical; isolation, particle-normalized dosing, potency, storage, biodistribution, and batch comparability were frequently incomplete. Magnification was not consistently standardized as a delivery variable. Relative readiness was highest for autologous DPSC pulp products, intermediate for DPSC-scaffold bone or periodontal products, and low for dental EV products. Translation now requires indication-specific potency assays, carrier-product codevelopment, dose–response and biodistribution studies, documented delivery fidelity, standardized outcomes, long-term safety follow-up, and explicit good manufacturing practice (GMP) and regulatory strategies before confirmatory trials.
- 12 October 2026
- Published by SAGE Publications in Stem Cells and Development
- Vol. 35 (23-24) , 445-458
Translational Readiness of Dental Pulp Stem Cell and Extracellular-Vesicle Products: Manufacturing, Delivery, Safety, and Clinical Development
Dental pulp stem cells (DPSCs), stem cells from human exfoliated deciduous teeth (SHED), and extracellular vesicles (EVs) show regenerative potential, but clinical translation depends on a reproducible product–process–procedure system. This systematic scoping review mapped how DPSC- and EV-containing dental products are defined, manufactured, formulated, dosed, delivered, monitored, and regulated. Following Joanna Briggs Institute guidance (JBI) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR), an umbrella-assisted strategy combined two recent high-coverage reviews with a targeted update through July 15, 2026. Data were charted for source, characterization, carrier, dose, delivery, visualization, safety, outcomes, and manufacturing readiness; a nine-domain review-level framework (Translational Readiness Appraisal for Dental cell and EV products) summarized relative maturity without serving as a validated clinical score. The map comprised 52 unique primary reports and nine methodological or secondary sources. Scaffold-based DPSC/SHED studies generally favored cell-containing constructs, but most were heterogeneous short-term animal experiments. Small human studies of autologous DPSC or SHED products reported encouraging feasibility and few serious safety signals, yet were underpowered for effectiveness or uncommon harms. Dental EV evidence remained predominantly preclinical; isolation, particle-normalized dosing, potency, storage, biodistribution, and batch comparability were frequently incomplete. Magnification was not consistently standardized as a delivery variable. Relative readiness was highest for autologous DPSC pulp products, intermediate for DPSC-scaffold bone or periodontal products, and low for dental EV products. Translation now requires indication-specific potency assays, carrier-product codevelopment, dose–response and biodistribution studies, documented delivery fidelity, standardized outcomes, long-term safety follow-up, and explicit good manufacturing practice (GMP) and regulatory strategies before confirmatory trials.
- Open Access
- 28 July 2026
- Published by SAGE Publications in Cell Transplantation
- Vol. 35
Stem cell and extracellular vesicle therapies for wound healing: An umbrella review of predominantly diabetic and preclinical evidence
Chronic and complex skin wounds, including diabetic ulcers and burns, represent a major clinical challenge with substantial morbidity and healthcare costs. Regenerative approaches have evolved from stem cell–based therapies toward stem cell–free strategies, particularly mesenchymal stroma/stem cell–derived extracellular vesicles (MSC-EVs). However, the relative strength, consistency, and translational readiness of these approaches remain unclear. The aim of this study is to synthesize and critically appraise evidence from systematic reviews and meta-analyses on cell-based and cell-free regenerative therapies for wound healing, with emphasis on clinical relevance, methodological quality, and recent developments. An umbrella review was conducted in accordance with PRISMA 2020 guidance. PubMed/MEDLINE, Scopus, and Web of Science were searched for systematic reviews and meta-analyses published in English within the last 5 years. Eligible reviews evaluated cell-based therapies and/or extracellular vesicle–based interventions for skin wound healing in clinical and/or animal models. Methodological quality was assessed using AMSTAR-2, and overlap of primary studies was evaluated using the corrected covered area (CCA). Seven systematic reviews and meta-analyses were included, encompassing both clinical and preclinical evidence. Notably, the majority of included evidence was derived from diabetic wound models, particularly in preclinical animal studies. Cell-based therapies demonstrated clinically relevant benefits in specific settings, such as autologous skin cell suspensions for burns and biologic skin substitutes for diabetic foot ulcers, although certainty of evidence was low to moderate. In contrast, MSC-EVs showed large and consistent effects on wound closure, angiogenesis, collagen deposition, and inflammatory modulation in preclinical models. No randomized human trials of EV-based wound therapies were identified. Current evidence suggests a paradigm shift toward stem cell–free regenerative strategies in wound healing. While cell therapies have limited but established clinical roles, MSC-EVs offer strong preclinical efficacy and translational potential. Standardization, regulatory alignment, and well-designed clinical trials are required to enable safe clinical implementation.
- 28 July 2026
- Published by SAGE Publications in Cell Transplantation
- Vol. 35
Open AccessStem cell and extracellular vesicle therapies for wound healing: An umbrella review of predominantly diabetic and preclinical evidence
Chronic and complex skin wounds, including diabetic ulcers and burns, represent a major clinical challenge with substantial morbidity and healthcare costs. Regenerative approaches have evolved from stem cell–based therapies toward stem cell–free strategies, particularly mesenchymal stroma/stem cell–derived extracellular vesicles (MSC-EVs). However, the relative strength, consistency, and translational readiness of these approaches remain unclear. The aim of this study is to synthesize and critically appraise evidence from systematic reviews and meta-analyses on cell-based and cell-free regenerative therapies for wound healing, with emphasis on clinical relevance, methodological quality, and recent developments. An umbrella review was conducted in accordance with PRISMA 2020 guidance. PubMed/MEDLINE, Scopus, and Web of Science were searched for systematic reviews and meta-analyses published in English within the last 5 years. Eligible reviews evaluated cell-based therapies and/or extracellular vesicle–based interventions for skin wound healing in clinical and/or animal models. Methodological quality was assessed using AMSTAR-2, and overlap of primary studies was evaluated using the corrected covered area (CCA). Seven systematic reviews and meta-analyses were included, encompassing both clinical and preclinical evidence. Notably, the majority of included evidence was derived from diabetic wound models, particularly in preclinical animal studies. Cell-based therapies demonstrated clinically relevant benefits in specific settings, such as autologous skin cell suspensions for burns and biologic skin substitutes for diabetic foot ulcers, although certainty of evidence was low to moderate. In contrast, MSC-EVs showed large and consistent effects on wound closure, angiogenesis, collagen deposition, and inflammatory modulation in preclinical models. No randomized human trials of EV-based wound therapies were identified. Current evidence suggests a paradigm shift toward stem cell–free regenerative strategies in wound healing. While cell therapies have limited but established clinical roles, MSC-EVs offer strong preclinical efficacy and translational potential. Standardization, regulatory alignment, and well-designed clinical trials are required to enable safe clinical implementation.
- Open Access
- 25 July 2026
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 54 (7)
Human clinical evidence on stem cell–based therapies for ischemic stroke: An umbrella review with emphasis on mesenchymal stem cells
Objective: To synthesize human clinical evidence from systematic reviews and meta-analyses on stem cell–based therapies for ischemic stroke, with an emphasis on mesenchymal stem cell–based interventions, and to appraise their efficacy, safety, methodological quality, overlap, and certainty of evidence. Methods: This Open Science Framework–registered umbrella review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 and Joanna Briggs Institute guidance. PubMed/MEDLINE, Scopus, and Web of Science were searched through 1 November 2025. Eligible studies were systematic reviews or meta-analyses of randomized or nonrandomized human clinical studies evaluating mesenchymal stem cells or related stem cell–based interventions for ischemic stroke. Two reviewers independently performed study selection, data extraction, AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews 2) appraisal, and GRADE (Grading of Recommendations Assessment, Development and Evaluation)-based certainty assessment. Because of overlap among reviews and heterogeneity in cell products, administration routes, timing, and outcomes, the findings were synthesized narratively rather than through a de novo meta-analysis. Results: Twenty-six reviews were included. The evidence suggested possible improvements in neurological impairment, disability, activities of daily living, and motor recovery; however, effect estimates varied according to cell type, administration route, timing after stroke, and follow-up duration. Intravenous administration was the most frequently studied and appeared feasible, with acceptable short-term safety reporting, whereas intra-arterial and intracerebral routes showed greater procedure-related concerns. Short-term adverse events were not consistently increased. However, the evidence remains insufficient regarding rare or delayed risks, including tumorigenesis, ectopic tissue formation, embolic events, and alloimmunogenicity. The certainty of evidence was low to moderate for most efficacy outcomes, moderate for short-term adverse events, and very low to low for long-term or rare safety outcomes. Conclusions: Stem cell–based therapies, particularly mesenchymal stem cell–based approaches, may improve selected neurological and functional outcomes after ischemic stroke. However, overlapping reviews, heterogeneous interventions, small early-phase trials, and limited long-term follow-up require cautious interpretation. Adequately powered, standardized, multicenter trials with long-term safety surveillance are needed before routine clinical implementation.
- 25 July 2026
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 54 (7)
Open AccessHuman clinical evidence on stem cell–based therapies for ischemic stroke: An umbrella review with emphasis on mesenchymal stem cells
Objective: To synthesize human clinical evidence from systematic reviews and meta-analyses on stem cell–based therapies for ischemic stroke, with an emphasis on mesenchymal stem cell–based interventions, and to appraise their efficacy, safety, methodological quality, overlap, and certainty of evidence. Methods: This Open Science Framework–registered umbrella review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 and Joanna Briggs Institute guidance. PubMed/MEDLINE, Scopus, and Web of Science were searched through 1 November 2025. Eligible studies were systematic reviews or meta-analyses of randomized or nonrandomized human clinical studies evaluating mesenchymal stem cells or related stem cell–based interventions for ischemic stroke. Two reviewers independently performed study selection, data extraction, AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews 2) appraisal, and GRADE (Grading of Recommendations Assessment, Development and Evaluation)-based certainty assessment. Because of overlap among reviews and heterogeneity in cell products, administration routes, timing, and outcomes, the findings were synthesized narratively rather than through a de novo meta-analysis. Results: Twenty-six reviews were included. The evidence suggested possible improvements in neurological impairment, disability, activities of daily living, and motor recovery; however, effect estimates varied according to cell type, administration route, timing after stroke, and follow-up duration. Intravenous administration was the most frequently studied and appeared feasible, with acceptable short-term safety reporting, whereas intra-arterial and intracerebral routes showed greater procedure-related concerns. Short-term adverse events were not consistently increased. However, the evidence remains insufficient regarding rare or delayed risks, including tumorigenesis, ectopic tissue formation, embolic events, and alloimmunogenicity. The certainty of evidence was low to moderate for most efficacy outcomes, moderate for short-term adverse events, and very low to low for long-term or rare safety outcomes. Conclusions: Stem cell–based therapies, particularly mesenchymal stem cell–based approaches, may improve selected neurological and functional outcomes after ischemic stroke. However, overlapping reviews, heterogeneous interventions, small early-phase trials, and limited long-term follow-up require cautious interpretation. Adequately powered, standardized, multicenter trials with long-term safety surveillance are needed before routine clinical implementation.
- Open Access
- 24 July 2026
- Published by Bentham Science Publishers Ltd. in The Open Medicinal Chemistry Journal
- Vol. 20 (1)
Integrated In-Silico Prioritization of Anti-Diabetic Candidates from Helianthus Tuberosus Using Bibliometrics, Target Prediction, Docking, MD, and ADMET Profiling
Introduction/Objective: Diabetes mellitus [DM] is a growing global burden associated with cardiovascular, neurological, and metabolic complications. Helianthus tuberosus [Jerusalem artichoke] contains inulin and bioactive phytochemicals that may modulate DM-related pathways. This study aimed to identify and prioritize candidate antidiabetic compounds through an integrated computational pipeline. Methods: Bibliometric analysis of Web of Science and Scopus records retrieved in February 2025 mapped research trends and prioritized candidate molecules. Protein targets were predicted using SwissTargetPrediction. Lead compounds underwent molecular docking with AutoDock Vina, 10-ns molecular dynamics simulations in GROMACS, pharmacokinetic and drug-likeness assessment using SwissADME, and toxicity prediction using ProTox-3 and Way2Drug. Results: “Fermentation,” “inulin,” and “metabolism” were the most frequent keywords. Six microbiome-derived metabolites generated through inulin fermentation and five plant phytochemicals were compiled. HDAC3, carbonic anhydrases, PTP1B, and EGLN1 emerged as relevant targets. Butyrate-HDAC3 and ferulic acid-CA XII formed stable complexes during molecular dynamics simulations [average RMSD ≤0.3 nm]. Both compounds had SwissADME bioavailability scores of 0.85, although ferulic acid showed suboptimal solubility. ProTox-3 classified butyrate as Toxicity Class 3 [predicted LD50 approximately 91 mg/kg], with possible blood-brain barrier liability; Way2Drug indicated potential multisystem adverse effects at higher exposures. Discussion: These findings suggest complementary antidiabetic mechanisms involving microbiome-derived metabolites and plant phytochemicals, but the computational predictions require experimental confirmation. Conclusion: Butyrate and ferulic acid were prioritised for mechanism-focused preclinical validation, with attention to butyrate toxicity and ferulic acid formulation.
- 24 July 2026
- Published by Bentham Science Publishers Ltd. in The Open Medicinal Chemistry Journal
- Vol. 20 (1)
Open AccessIntegrated In-Silico Prioritization of Anti-Diabetic Candidates from Helianthus Tuberosus Using Bibliometrics, Target Prediction, Docking, MD, and ADMET Profiling
Introduction/Objective: Diabetes mellitus [DM] is a growing global burden associated with cardiovascular, neurological, and metabolic complications. Helianthus tuberosus [Jerusalem artichoke] contains inulin and bioactive phytochemicals that may modulate DM-related pathways. This study aimed to identify and prioritize candidate antidiabetic compounds through an integrated computational pipeline. Methods: Bibliometric analysis of Web of Science and Scopus records retrieved in February 2025 mapped research trends and prioritized candidate molecules. Protein targets were predicted using SwissTargetPrediction. Lead compounds underwent molecular docking with AutoDock Vina, 10-ns molecular dynamics simulations in GROMACS, pharmacokinetic and drug-likeness assessment using SwissADME, and toxicity prediction using ProTox-3 and Way2Drug. Results: “Fermentation,” “inulin,” and “metabolism” were the most frequent keywords. Six microbiome-derived metabolites generated through inulin fermentation and five plant phytochemicals were compiled. HDAC3, carbonic anhydrases, PTP1B, and EGLN1 emerged as relevant targets. Butyrate-HDAC3 and ferulic acid-CA XII formed stable complexes during molecular dynamics simulations [average RMSD ≤0.3 nm]. Both compounds had SwissADME bioavailability scores of 0.85, although ferulic acid showed suboptimal solubility. ProTox-3 classified butyrate as Toxicity Class 3 [predicted LD50 approximately 91 mg/kg], with possible blood-brain barrier liability; Way2Drug indicated potential multisystem adverse effects at higher exposures. Discussion: These findings suggest complementary antidiabetic mechanisms involving microbiome-derived metabolites and plant phytochemicals, but the computational predictions require experimental confirmation. Conclusion: Butyrate and ferulic acid were prioritised for mechanism-focused preclinical validation, with attention to butyrate toxicity and ferulic acid formulation.
- 23 July 2026
- Published by BMJ in Injury Prevention
Hospital-based fall prevention interventions in paediatric patients: a systematic review and meta-analysis
Background/aims: Falls among paediatric inpatients represent a significant safety concern, contributing to prolonged hospitalisations and increased healthcare costs. This systematic review and meta-analysis aimed to evaluate the effectiveness of hospital-based fall prevention interventions for paediatric inpatients. Methods: Nine studies, including quality improvement projects, experimental/quasi-experimental studies and retrospective analyses, were included after a comprehensive search of Scopus, Web of Science and PubMed databases. Interventions such as risk-stratified protocols, visual identifiers, enhanced surveillance and caregiver education were assessed. Two reviewers independently performed screening, data extraction and risk of bias assessment, and disagreements were resolved by consensus. Results: The meta-analysis (random-effects model with Hartung-Knapp adjustment) showed no statistically significant association between hospital-based interventions and fall outcomes (OR=1.81, 95% CI 0.57 to 5.77), with substantial heterogeneity (I²=91.4%, p<0.0001). Evidence on commonly used paediatric fall-risk screening tools was summarised narratively, indicating high sensitivity but limited specificity for the Humpty Dumpty Fall Scale and more balanced diagnostic performance for the Paediatric Fall Assessment Scale. Multicomponent interventions combining risk assessment, caregiver involvement, staff education and environmental modifications showed the most consistent effects, while single-component or short-term interventions were less effective. Contextual factors such as hospital infrastructure, staffing patterns and safety culture also appeared to influence outcomes. Conclusions: Despite promising results, short-term interventions and lack of standardisation highlight the need for tailored, evidence-based strategies. Our findings underscore the importance of integrating both targeted high-risk approaches and universal hospital-wide safety measures. PROSPERO registration number: CRD420251071227.
- 23 July 2026
- Published by BMJ in Injury Prevention
Hospital-based fall prevention interventions in paediatric patients: a systematic review and meta-analysis
Background/aims: Falls among paediatric inpatients represent a significant safety concern, contributing to prolonged hospitalisations and increased healthcare costs. This systematic review and meta-analysis aimed to evaluate the effectiveness of hospital-based fall prevention interventions for paediatric inpatients. Methods: Nine studies, including quality improvement projects, experimental/quasi-experimental studies and retrospective analyses, were included after a comprehensive search of Scopus, Web of Science and PubMed databases. Interventions such as risk-stratified protocols, visual identifiers, enhanced surveillance and caregiver education were assessed. Two reviewers independently performed screening, data extraction and risk of bias assessment, and disagreements were resolved by consensus. Results: The meta-analysis (random-effects model with Hartung-Knapp adjustment) showed no statistically significant association between hospital-based interventions and fall outcomes (OR=1.81, 95% CI 0.57 to 5.77), with substantial heterogeneity (I²=91.4%, p<0.0001). Evidence on commonly used paediatric fall-risk screening tools was summarised narratively, indicating high sensitivity but limited specificity for the Humpty Dumpty Fall Scale and more balanced diagnostic performance for the Paediatric Fall Assessment Scale. Multicomponent interventions combining risk assessment, caregiver involvement, staff education and environmental modifications showed the most consistent effects, while single-component or short-term interventions were less effective. Contextual factors such as hospital infrastructure, staffing patterns and safety culture also appeared to influence outcomes. Conclusions: Despite promising results, short-term interventions and lack of standardisation highlight the need for tailored, evidence-based strategies. Our findings underscore the importance of integrating both targeted high-risk approaches and universal hospital-wide safety measures. PROSPERO registration number: CRD420251071227.
- 17 June 2026
- Published by SAGE Publications in Molecular Imaging
- Vol. 25
Radiomic Analysis of MRI for Assessing Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma: A Systematic Review and Metaanalysis
Background: This study aimed to evaluate the diagnostic performance of magnetic resonance imaging (MRI)-based radiomics for predicting pathological complete response (pCR) after neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. Methods: Eligible studies developed MRI-based radiomics or deep learning models to predict pCR and reported sufficient data to reconstruct 2 × 2 contingency tables. Only validation cohorts were included in the quantitative synthesis. Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 and the Radiomics Quality Score. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio were estimated using a bivariate random-effects model. Hierarchical summary receiver operating characteristic (HSROC) analysis was performed. Results: Thirty-eight studies were included. The pooled sensitivity and specificity were 0.82 (95% CI, 0.71-0.90) and 0.86 (95% CI, 0.80-0.91), respectively. The pooled PLR and NLR were 6.0 (95% CI, 4.0-8.9) and 0.21 (95% CI, 0.12-0.35), corresponding to a diagnostic odds ratio of 29 (95% CI, 14-61). HSROC analysis showed an area under the curve of 0.846. Subgroup analyses suggested improved performance for deep learning and combined clinical–radiomic models. Conclusion: MRI-based radiomics demonstrates good diagnostic accuracy for predicting pCR after neoadjuvant chemoradiotherapy in rectal cancer, although methodological heterogeneity and limited prospective validation remain challenges.
- 17 June 2026
- Published by SAGE Publications in Molecular Imaging
- Vol. 25
Radiomic Analysis of MRI for Assessing Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma: A Systematic Review and Metaanalysis
Background: This study aimed to evaluate the diagnostic performance of magnetic resonance imaging (MRI)-based radiomics for predicting pathological complete response (pCR) after neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. Methods: Eligible studies developed MRI-based radiomics or deep learning models to predict pCR and reported sufficient data to reconstruct 2 × 2 contingency tables. Only validation cohorts were included in the quantitative synthesis. Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 and the Radiomics Quality Score. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio were estimated using a bivariate random-effects model. Hierarchical summary receiver operating characteristic (HSROC) analysis was performed. Results: Thirty-eight studies were included. The pooled sensitivity and specificity were 0.82 (95% CI, 0.71-0.90) and 0.86 (95% CI, 0.80-0.91), respectively. The pooled PLR and NLR were 6.0 (95% CI, 4.0-8.9) and 0.21 (95% CI, 0.12-0.35), corresponding to a diagnostic odds ratio of 29 (95% CI, 14-61). HSROC analysis showed an area under the curve of 0.846. Subgroup analyses suggested improved performance for deep learning and combined clinical–radiomic models. Conclusion: MRI-based radiomics demonstrates good diagnostic accuracy for predicting pCR after neoadjuvant chemoradiotherapy in rectal cancer, although methodological heterogeneity and limited prospective validation remain challenges.
- Open Access
- 17 June 2026
- Published by Wiley in Nursing Open
- Vol. 13 (6) , e70648
Quality of Primary Healthcare Services in Kazakhstan: A Systematic Review and Meta‐Analysis of Patient‐Centred Outcomes and Implications for Nursing Practice and Policy
Aims: To systematically evaluate the quality, accessibility and patient‐centred performance of primary healthcare services in Kazakhstan and to generate pooled quantitative estimates of key patient‐centred and system‐level outcomes, with specific attention to their implications for primary healthcare nursing practice, nurse‐led quality improvement and nursing policy. Design: Systematic review and meta‐analysis conducted in accordance with PRISMA guidelines. Data Sources: Scopus, Web of Science and PubMed were systematically searched for eligible studies published between January 2015 and December 2025. Review Methods: Observational, cross‐sectional, mixed‐methods and interventional studies assessing PHC quality domains in Kazakhstan were included. Two reviewers independently screened studies, extracted data and assessed methodological quality using the Joanna Briggs Institute (JBI) appraisal tools for observational studies and the Cochrane RoB 2 tool for the cluster‐randomized trial. Random‐effects meta‐analyses were conducted for (1) patient‐centred outcomes and (2) system‐level PHC performance indicators. Statistical heterogeneity was assessed using the I 2 statistic, and publication bias was evaluated using funnel plots. Results: Eight studies met the inclusion criteria and were included in the qualitative synthesis and meta‐analysis. Four studies contributed data on patient‐centred outcomes, yielding a pooled patient satisfaction proportion of 0.56 (95% CI: 0.53–0.59; I 2 = 48.7%). Four studies reported system‐level performance indicators, with a pooled estimate of 0.64 (95% CI: 0.52–0.75; I 2 = 98.4%). Funnel plots were used for descriptive purposes only and were interpreted cautiously, as each meta‐analysis included only four studies, making reliable assessment of publication bias not feasible. Conclusion: This systematic review and meta‐analysis provides the first consolidated quantitative assessment of PHC quality in Kazakhstan. While patient satisfaction and system‐level performance appear moderate, substantial heterogeneity and regional disparities remain. Strengthening PHC quality will require standardized performance indicators, enhanced digital health integration and targeted interventions to reduce urban–rural inequalities. Impact: The findings of this study have important implications for clinical nursing practice and healthcare management. Given the central role of primary healthcare nurses in patient communication, care coordination, chronic disease monitoring, and preventive services, the identified gaps in patient satisfaction and system‐level performance highlight key areas for nursing‐led improvement. Enhancing nurse involvement in patient education, continuity of care, and service accessibility may contribute to improved patient experiences and health outcomes. These findings support the need for strengthening nursing capacity, expanding nurse‐led models of care and integrating nursing perspectives into PHC quality improvement strategies within Kazakhstan's evolving healthcare system. Patient or Public Contribution: Not applicable.
- 17 June 2026
- Published by Wiley in Nursing Open
- Vol. 13 (6) , e70648
Open AccessQuality of Primary Healthcare Services in Kazakhstan: A Systematic Review and Meta‐Analysis of Patient‐Centred Outcomes and Implications for Nursing Practice and Policy
Aims: To systematically evaluate the quality, accessibility and patient‐centred performance of primary healthcare services in Kazakhstan and to generate pooled quantitative estimates of key patient‐centred and system‐level outcomes, with specific attention to their implications for primary healthcare nursing practice, nurse‐led quality improvement and nursing policy. Design: Systematic review and meta‐analysis conducted in accordance with PRISMA guidelines. Data Sources: Scopus, Web of Science and PubMed were systematically searched for eligible studies published between January 2015 and December 2025. Review Methods: Observational, cross‐sectional, mixed‐methods and interventional studies assessing PHC quality domains in Kazakhstan were included. Two reviewers independently screened studies, extracted data and assessed methodological quality using the Joanna Briggs Institute (JBI) appraisal tools for observational studies and the Cochrane RoB 2 tool for the cluster‐randomized trial. Random‐effects meta‐analyses were conducted for (1) patient‐centred outcomes and (2) system‐level PHC performance indicators. Statistical heterogeneity was assessed using the I 2 statistic, and publication bias was evaluated using funnel plots. Results: Eight studies met the inclusion criteria and were included in the qualitative synthesis and meta‐analysis. Four studies contributed data on patient‐centred outcomes, yielding a pooled patient satisfaction proportion of 0.56 (95% CI: 0.53–0.59; I 2 = 48.7%). Four studies reported system‐level performance indicators, with a pooled estimate of 0.64 (95% CI: 0.52–0.75; I 2 = 98.4%). Funnel plots were used for descriptive purposes only and were interpreted cautiously, as each meta‐analysis included only four studies, making reliable assessment of publication bias not feasible. Conclusion: This systematic review and meta‐analysis provides the first consolidated quantitative assessment of PHC quality in Kazakhstan. While patient satisfaction and system‐level performance appear moderate, substantial heterogeneity and regional disparities remain. Strengthening PHC quality will require standardized performance indicators, enhanced digital health integration and targeted interventions to reduce urban–rural inequalities. Impact: The findings of this study have important implications for clinical nursing practice and healthcare management. Given the central role of primary healthcare nurses in patient communication, care coordination, chronic disease monitoring, and preventive services, the identified gaps in patient satisfaction and system‐level performance highlight key areas for nursing‐led improvement. Enhancing nurse involvement in patient education, continuity of care, and service accessibility may contribute to improved patient experiences and health outcomes. These findings support the need for strengthening nursing capacity, expanding nurse‐led models of care and integrating nursing perspectives into PHC quality improvement strategies within Kazakhstan's evolving healthcare system. Patient or Public Contribution: Not applicable.
- Open Access
- 30 March 2026
- Published by AMG Transcend Association in Letters in Applied NanoBioScience
- Vol. 15 (1)
The Mathematical Model for Thiabendazole Electrochemical Determination in Pharmaceutical Formulations, Biological Liquids and Food Products
In this work, the electrochemical determination of thiabendazole in pharmaceutical formulations, biological liquids, and food has been described using a mathematical model, which was thereby analyzed using linear stability theory and bifurcation analysis. Three scenarios, including N-oxidation, S-oxidation, and electropolymerization, have been included in the model. The model analysis shows that, despite the presence of the electropolymerization scenario and the increase in the probability of oscillatory behavior, the electroanalytical process, performed anodically on copper sulfide nanoparticles, is efficient and may be used for both electrochemical determination and excess removal of thiabendazole. As for poly(thiobendazole), it is suitable for the determination and removal of heavy metal ions.
- 30 March 2026
- Published by AMG Transcend Association in Letters in Applied NanoBioScience
- Vol. 15 (1)
Open AccessThe Mathematical Model for Thiabendazole Electrochemical Determination in Pharmaceutical Formulations, Biological Liquids and Food Products
In this work, the electrochemical determination of thiabendazole in pharmaceutical formulations, biological liquids, and food has been described using a mathematical model, which was thereby analyzed using linear stability theory and bifurcation analysis. Three scenarios, including N-oxidation, S-oxidation, and electropolymerization, have been included in the model. The model analysis shows that, despite the presence of the electropolymerization scenario and the increase in the probability of oscillatory behavior, the electroanalytical process, performed anodically on copper sulfide nanoparticles, is efficient and may be used for both electrochemical determination and excess removal of thiabendazole. As for poly(thiobendazole), it is suitable for the determination and removal of heavy metal ions.
- 25 March 2026
- Published by SAGE Publications in Journal of Neonatal-Perinatal Medicine
- Vol. 19 (6) , 583-596
Artificial intelligence in Prechtl’s General Movements Assessment: A systematic review and meta-analysis
Objective: To evaluate AI-assisted GMA performance for (i) prediction of later cerebral palsy (CP) diagnosis and (ii) classification of expert-rated GMA labels, and to assess heterogeneity and risk of bias. Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. A total of 105 studies were included in qualitative synthesis, of which 28 were eligible for quantitative synthesis. Random-effects meta-analysis of proportions with logit transformation was used to estimate pooled diagnostic accuracy. Results: Of 105 eligible studies in qualitative synthesis, 28 were included in quantitative synthesis (17 CP diagnosis outcomes; 11 expert GMA label outcomes). For CP diagnosis outcomes, the pooled diagnostic accuracy was 0.884 (95% CI: 0.838–0.918). For expert-rated GMA label outcomes, the pooled classification accuracy was 0.848 (95% CI: 0.761–0.908). Heterogeneity was substantial across analyses. Interpretation: AI-assisted GMA shows high pooled performance for both CP diagnosis prediction and expert-label classification; however, certainty remains very low due to heterogeneity and risk of bias. No single GM developmental phase, or sensor modality, demonstrated clear superiority, underscoring the importance of standardized protocols, high-quality datasets, and transparent validation. These findings support the clinical potential of AI-enabled GMA as an objective and scalable screening tool, particularly in settings with limited access to specialized expertise.
- 25 March 2026
- Published by SAGE Publications in Journal of Neonatal-Perinatal Medicine
- Vol. 19 (6) , 583-596
Artificial intelligence in Prechtl’s General Movements Assessment: A systematic review and meta-analysis
Objective: To evaluate AI-assisted GMA performance for (i) prediction of later cerebral palsy (CP) diagnosis and (ii) classification of expert-rated GMA labels, and to assess heterogeneity and risk of bias. Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. A total of 105 studies were included in qualitative synthesis, of which 28 were eligible for quantitative synthesis. Random-effects meta-analysis of proportions with logit transformation was used to estimate pooled diagnostic accuracy. Results: Of 105 eligible studies in qualitative synthesis, 28 were included in quantitative synthesis (17 CP diagnosis outcomes; 11 expert GMA label outcomes). For CP diagnosis outcomes, the pooled diagnostic accuracy was 0.884 (95% CI: 0.838–0.918). For expert-rated GMA label outcomes, the pooled classification accuracy was 0.848 (95% CI: 0.761–0.908). Heterogeneity was substantial across analyses. Interpretation: AI-assisted GMA shows high pooled performance for both CP diagnosis prediction and expert-label classification; however, certainty remains very low due to heterogeneity and risk of bias. No single GM developmental phase, or sensor modality, demonstrated clear superiority, underscoring the importance of standardized protocols, high-quality datasets, and transparent validation. These findings support the clinical potential of AI-enabled GMA as an objective and scalable screening tool, particularly in settings with limited access to specialized expertise.
- 24 March 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105294
Various applications of stem-cell-targeted radioimmunotherapy for the treatment of cancer: A narrative review
- 24 March 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105294
Various applications of stem-cell-targeted radioimmunotherapy for the treatment of cancer: A narrative review